Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat as GVHD Prophylaxis in Non-Malignant Disorders Undergoing Allogeneic BMT
NCT06995521Phase 2Recruiting
- Start
- Dec 2026
- Primary completion
- Sep 2028
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in graft-versus-host disease (GVHD). Primary endpoints: GVHD-free relapse-free Survival at 1 year, Primary graft failure/rejection at Day 42 and 1 more. Planned start Dec 2026; status: recruiting.
02
Drugs
vorinostat
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06995521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06995521.